Lipophilic anesthetic agents exhibit increased volumes of distribution with risk of accumulation in patients with obesity
The paper reports that excess adiposity induces drug-specific alterations in distribution, hepatic clearance, and renal elimination. Lipophilic agents show increased volumes of distribution in obese patients, leading to a risk of drug accumulation.
Evidence Score
Study Evidence
Study 1. Perioperative drug pharmacokinetics in patients with obesity.
observationalRousseleau D, De Baerdemaeker L · Current opinion in clinical nutrition and metabolic care (2026)
Result:
Mechanism Graph
Limitations
- ⚠The paper is a review and does not provide original quantitative data
- ⚠Pharmacokinetic evidence remains limited for several commonly used drugs like ketamine, magnesium sulfate, and dexamethasone
Frequently Asked Questions
Why do lipophilic drugs accumulate in obese patients?▼
Lipophilic drugs distribute into excess adipose tissue, increasing their volume of distribution and prolonging elimination, which can lead to accumulation.
What is the recommended dosing strategy for obese patients?▼
The paper recommends an individualized approach based on pharmacokinetic principles and clinical titration, avoiding dosing based solely on total body weight for hydrophilic drugs.
Are opioids safe for obese patients?▼
The paper advises restrictive use or avoidance of opioids due to the high incidence of sleep apnea in obese patients.
Which drugs have limited pharmacokinetic data in obesity?▼
Ketamine, magnesium sulfate, and dexamethasone have limited pharmacokinetic evidence in patients with obesity.
Products
Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.
References
- 1.Rousseleau D, De Baerdemaeker L. "Perioperative drug pharmacokinetics in patients with obesity.." Current opinion in clinical nutrition and metabolic care, 2026. PMID: 41995285 DOI: 10.1097/MCO.0000000000001225